Efficacy of Half Dose and One Third Dose of Injection Taurolock® for Tunneled Double Lumen Catheter Lock Solution
DOI:
https://doi.org/10.51253/pafmj.v75iSUPPL-6.12594Keywords:
Catheter Related Infection, Hemodialysis, TaurolidineAbstract
Objective: To compare the efficacy of TaurolockHEP500®, as half and one third of standard dose on prevention of catheter related blood stream infection (CRBSI) and catheter dysfunction in patients undergoing hemodialysis via tunneled double lumen catheter.
Study Design: Quasi-experimental study.
Place and Duration of Study: Department of Nephrology, Armed Forces Institute of Urology, Rawalpindi, Pakistan, and Pak Emirates Military Hospital Rawalpindi, Pakistan from Sep, 2023 to Apr, 2024.
Methodology: The study recruited 314 patients, were divided into two groups; Group-A (n=157) and Group-B (n=157). Injection TaurolockHEP500® was administered into the tunneled double lumen catheter as half doses for Group-A and one third doses for Group-B. The rest of the space in catheter’s lumen was filled with heparin. All the patients were then followed for 3 months. Blood samples for culture and sensitivity, were taken from both ports of their tunneled catheters and from a peripheral vein simultaneously to confirm CRBSI during fever spike in hemodialysis. Moreover, blood flow rates were monitored during each session to detect catheter dysfunction.
Results: Catheter function and blood culture didn’t show a significant difference among two study groups (Group-A and Group-B) with p-values 0.702 and 0.556 respectively.
Conclusion: The catheter lock solution TaurolockHEP500® even in one third dose, after each session of hemodialysis, can significantly reduce the rate of bacteremia and catheter dysfunction.
Downloads
References
1. Busink E, Kendzia D, Kircelli F, Boeger S, Petrovic J, Smethurst H, et al. A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway. Eur. J. Health Econ 2023: 377-392.
https://doi.org/10.1007/s10198-022-01478-2
2. AlRashed H, Miele J, Prasad J, Adenikinju D, Iloegbu C, Patena J, et al. Systematic review of end stage renal disease in Pakistan: Identifying implementation research outcomes. PLoS One 2023: 1-10.
https://doi.org/10.1371/journal.pone.0296243
3. Ali A, Wifaq HK, Alam AT, Waraich TA, Kathia UM, Gill MR, et al. Factors Affecting On Dialysis Patients to Choose or Refuse Kidney Transplantation as Renal Replacement Therapy: Factors Affecting on Dialysis Patients. Pak. J. of Health Sci 2023: 73-77.
https://doi.org/10.54393/pjhs.v4i03.526
4. Dahlan KM, Yusuf FJ, Rahman A, Rayka I, Sholekhuddin W. Characteristic of Catheter Double Lumen Infection In Chronic Kidney Disease Patients At Dr. Mohammad Hoesin Hospital Palembang. Contagion: Sci. Period. J. of Public Health and Coastal Health 2023: 451-461.
http://jurnal.uinsu.ac.id/index.php/contagion
5. Putra IG, Soebroto H, Yan Efrata Sembiring Y, Limanto DH, Hakim AR et al. The longevity of temporary hemodialysis catheters by insertion site in patients undergoing hemodialysis: systematic review. Ital. J. Vasc. Endovac 2023: 100-106.
https://doi.org/10.23736/S1824-4777.23.01600-5
6. Borisov BK, Vasileva VT. Hemodialysis tunneled catheters lock with TauroLock™ versus a combination of gentamycine and heparine. J. of IMAB 2023: 5045-5048.
https://doi.org/10.5272/jimab.2023293.5045
7. Shahar S, Mustafar R, Kamaruzaman L, Periyasamy P, Pau KB, Ramli R. Catheter‐Related Bloodstream Infections and Catheter Colonization among Haemodialysis Patients: Prevalence, Risk Factors, and Outcomes. Int. J. Nephrol 2021: 556-560.
https://doi.org/10.1155/2021/5562690
8. Al-Ali F, Hamdy AF, Hamad A, Elsayed M, Zafar Iqbal Z, Elsayed A, et al. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study. Nephrol. Dial Transplant 2018: 619-626.
https://doi.org/10.1093/ndt/gfx187
9. Agarwal AK, Roy-Chaudhury P, Mounts P, Hurlburt E, Pfaffle A, Poggio EC et al. Taurolidine/heparin lock solution and catheter-related bloodstream infection in hemodialysis: a randomized, double-blind, active-control, phase 3 study. Clin. J. Am. Soc. Nephrol 2023: 1446-55.
https://doi.org/10.2215/CJN.0000000000000278
10. Bonkain F, Stolear JC, Catalano C, Vandervelde D, Treille S, Couttenye MM, et al. Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: a randomized double-blind trial. PLoS One 2021: 251-260.
https://doi.org/10.1371/journal.pone.0251793
11. Golmohamadi S, Omrani HR, Asadi N, Sharifi E, Zandkarimi MR. Half dose of TauroLock; does it work? J. Renal Inj. Prev 2018: 180-185.
https://doi.org/10.15171/jrip.2018.43
12. Fontseré N, Cardozo C, Donate J, Soriano A, Muros M, Pons M, et al. Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients. Antimicrob. Agents Chemother 2014: 4180-4184. https://doi.org/10.1128/aac.02421-14
13. Zwiech R, Adelt M, Chrul S. A Taurolidine–Citrate–Heparin Lock Solution Effectively Eradicates Pathogens From the Catheter Biofilm in Hemodialysis Patients. Am. J. Ther 2016: 363-368. https://doi.org/10.1097/MJT.0b013e31828d4610
14. Kavosi Z, Sarikhani Khorrami M, Keshavarz Kh, Jafari A, Hashemi Meshkini A, Safaei HR, et al. Is Taurolidine-citrate an effective and cost-effective hemodialy-sis catheter lock solution? A systematic review and cost- effectiveness analysis. Med. J. Islam Repub. Iran 2016: 347-358. http://mjiri.iums.ac.ir/
15. Van den Bosch CH, Jeremiasse B, van der Bruggen JT, Frakking FNJ, Loeffen YGT, van de Ven CP, et al. The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis. J. Hosp. Infect 2022: 143-155. https://doi.org/10.1016/j.jhin.2021.10.022
16. Liu J, Wang C, Zhao H, Zhang J, Ma J, Hou Y, et al. Anticoagulant therapies versus heparin for the prevention of hemodialysis catheter-related complications: systematic review and meta-analysis of prospective randomized controlled trials. Int. J. Clin. Exp. Med 2015: 11985-11995. PMID:26550111
17. Bonkain F, Stolear JC, Catalano C, Vandervelde D, Treille S, Couttenye MM, et al. Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: A randomized double-blind trial. PLoS One. 2021: 251-263.
https://doi.org/10.1371/journal.pone.0251793
18. Murray EC, Deighan C, Geddes C, Thomson PC. Taurolidine-citrate-heparin catheter lock solution reduces staphylococcal bacteremia rates in hemodialysis patients. QJM 2014: 995-1000. https://doi.org/10.1093/qjmed/hcu128
19. Corbett R, Ashby D, Edwards C, Prout V, Singh S, Bedi R et al. A randomised control trial of taurolidine-heparin-citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients. Vascular access 2013: 19-24.
Downloads
Published
License
Copyright (c) 2025 Ghulam Mustafa, Nauman Kashif, Sohail Sabir, Farrukh Islam, Ruqaiyya Nazir, Muhammad Iqbal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
